| [1] |
KMEID M, LIU X, BALLENTINE S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data[J]. Gastroenterology Res, 2021, 14(2): 49-65. DOI: 10.14740/gr1376. |
| [2] |
de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0. |
| [3] |
WÖRAN K, SEMMLER G, JACHS M, et al. Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e251-e266. DOI: 10.1016/j.cgh.2020.11.039. |
| [4] |
HERNÁNDEZ-GEA V, BAIGES A, TURON F, et al. Idiopathic portal hypertension[J]. Hepatology, 2018, 68(6): 2413-2423. DOI: 10.1002/hep.30132. |
| [5] |
HERNÁNDEZ-GEA V, CAMPRECIÓS G, BETANCOURT F, et al. Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease[J]. J Hepatol, 2021, 75(4): 924-934. DOI: 10.1016/j.jhep.2021.05.014. |
| [6] |
CARNEVALE R, RAPARELLI V, NOCELLA C, et al. Gut-derived endotoxin stimulates factor VⅢ secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. DOI: 10.1016/j.jhep.2017.07.002. |
| [7] |
LEONARDI F, MARIA N, VILLA E. Anticoagulation in cirrhosis: a new paradigm?[J]. Clin Mol Hepatol, 2017, 23(1): 13-21. DOI: 10.3350/cmh.2016.0110. |
| [8] |
CERINI F, GONZALEZ JM, TORRES F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study[J]. Hepatology, 2015, 62(2): 575-583. DOI: 10.1002/hep.27783. |
| [9] |
GAO Y, LIU H, TANG F, et al. Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101649. DOI: 10.1016/j.clinre.2021.101649. |
| [10] |
HIDE D, WARREN A, FERNÁNDEZ-IGLESIAS A, et al. Ischemia/reperfusion injury in the aged liver: the importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly[J]. J Gerontol A Biol Sci Med Sci, 2020, 75(2): 268-277. DOI: 10.1093/gerona/glz012. |
| [11] |
POSE E, TREBICKA J, MOOKERJEE RP, et al. Statins: Old drugs as new therapy for liver diseases?[J]. J Hepatol, 2019, 70(1): 194-202. DOI: 10.1016/j.jhep.2018.07.019. |
| [12] |
BUNCHORNTAVAKUL C, REDDY KR. Pharmacologic management of portal hypertension[J]. Clin Liver Dis, 2019, 23(4): 713-736. DOI: 10.1016/j.cld.2019.06.004. |
| [13] |
HAN Y, CHEN J, QIU M, et al. Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: The OPT-CAD risk score[J]. Cardiovasc Ther, 2018, 36(5): e12441. DOI: 10.1111/1755-5922.12441. |
| [14] |
KUMAR S, GRACE ND, QAMAR AA. Statin use in patients with cirrhosis: a retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965. DOI: 10.1007/s10620-014-3179-2. |
| [15] |
MUÑOZ AE, POLLARSKY FD, MARINO M, et al. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy[J]. World J Gastroenterol, 2021, 27(28): 4639-4652. DOI: 10.3748/wjg.v27.i28.4639. |
| [16] |
GIOIA S, NARDELLI S, RIDOLA L, et al. Causes and management of non-cirrhotic portal hypertension?[J]. Curr Gastroenterol Rep, 2020, 22(12): 56. DOI: 10.1007/s11894-020-00792-0. |
DownLoad: